```html

Xanthinuria‑Related Kidney Stones

What is Xanthinuria‑related kidney stones?

Xanthinuria‑related kidney stones are a rare type of urinary stone composed primarily of the purine metabolite xanthine. Xanthine is a normal intermediate in the breakdown of purine nucleotides (DNA, RNA) to uric acid. In people with xanthinuria – a hereditary or acquired deficiency of the enzymes xanthine oxidase or aldehyde oxidase – xanthine accumulates in the blood and urine, becomes supersaturated, and crystallises inside the renal pelvis or ureters, forming stones.

Because xanthine is far less soluble than uric acid, even modest increases in urinary concentration can lead to stone formation. These stones are typically radiolucent on plain X‑ray, may appear on ultrasound, and are identified by their chemical composition after retrieval.

Although xanthinuria accounts for < 1% of all kidney‑stone cases, recognising it is crucial because the condition is treatable and, if left unchecked, can lead to chronic kidney disease or recurrent obstruction.

Common Causes

The primary cause is a deficiency of enzymes that convert xanthine to uric acid. The following conditions or factors can lead to xanthinuria‑related stones:

• Type I Xanthinuria (XDH deficiency) – Autosomal recessive mutation in the XDH gene causing loss of xanthine oxidase activity.
• Type II Xanthinuria (combined XDH & aldehyde oxidase deficiency) – Mutations in the MOCOS gene affect both enzymes.
• Acquired enzyme inhibition – Long‑term use of xanthine oxidase inhibitors such as allopurinol or febuxostat can mimic the metabolic block.
• Severe liver disease – Impaired hepatic metabolism can reduce enzyme activity.
• High‑purine diet – Excess intake of meat, seafood, organ meats, and certain legumes raises xanthine production.
• Dehydration – Low urine volume concentrates xanthine, increasing the risk of crystallisation.
• Genetic syndromes affecting purine metabolism – e.g., Lesch‑Nyhan syndrome (HGPRT deficiency) can elevate purine intermediates.
• Renal tubular acidosis (type I) – Alters urinary pH and promotes stone formation.
• Medications causing increased purine turnover – Cytotoxic drugs (e.g., 6‑mercaptopurine) can raise intracellular purines.
• Obstructive uropathy – Stasis of urine provides more time for xanthine crystals to aggregate.

Associated Symptoms

Patients with xanthinuria‑related stones often experience the same classic renal‑colic symptoms as other stone formers, plus a few clues that point toward a purine disorder.

• Sudden, severe flank or lower‑abdominal pain that may radiate to the groin.
• Nausea, vomiting, or decreased appetite.
• Hematuria (visible or microscopic blood in the urine).
• Urgency or frequency of urination if the stone irritates the bladder.
• Passage of white‑to‑light‑yellow granules in the urine – xanthine stones are often described as “chalky”.
• Recurrent stone episodes despite normal calcium or oxalate levels.
• Fatigue or mild muscle pain, which can accompany systemic purine‑metabolism disturbances.

When to See a Doctor

Kidney‑stone pain is a medical emergency only when accompanied by warning signs. Seek care promptly if you notice any of the following:

• Persistent pain lasting more than 6 hours and not relieved by over‑the‑counter pain meds.
• Fever ≥ 38 °C (100.4 °F) or chills, indicating possible infection.
• Difficulty passing urine or a sudden drop in urine output.
• Severe vomiting preventing oral intake.
• Blood pressure spikes (> 160/100 mmHg) or a rapid heart rate (> 110 bpm) with pain.
• Known diagnosis of xanthinuria with new or worsening flank pain.

Diagnosis

Because xanthine stones are radiolucent, a combination of imaging and laboratory tests is required.

1. Imaging

• Non‑contrast helical CT scan – Gold standard for detecting stone size, location, and obstruction.
• Ultrasound – Useful in children, pregnant women, and for follow‑up of known stones.
• Non‑contrast plain X‑ray – Often negative for xanthine stones, helping differentiate them from calcium‑based stones.

2. Laboratory Evaluation

• Urine chemistry – Spot urine or 24‑hour collection showing elevated xanthine concentration (> 0.2 mmol/L) with normal or low uric acid.
• Serum studies – Normal serum uric acid, normal renal function unless obstruction has caused injury.
• Enzyme assays – Genetic testing for XDH or MOCOS mutations confirms hereditary xanthinuria.
• Stone analysis – Infrared spectroscopy or X‑ray diffraction after stone retrieval validates xanthine composition.

3. Additional Work‑up

• Complete metabolic panel to rule out other stone‑forming disorders.
• Urine pH measurement (xanthine stones form over a broad pH range, but a pH < 6 may slightly reduce solubility).

Treatment Options

Treatment aims to relieve obstruction, prevent new stone formation, and address the underlying metabolic defect.

Acute Management

• Pain control – NSAIDs (e.g., ibuprofen 400–600 mg q6‑8 h) or opioids if needed, under physician supervision.
• Hydration – Intravenous isotonic saline (1–2 L over the first 24 h) to encourage diuresis.
• Medical expulsive therapy – Alpha‑blocker (tamsulosin 0.4 mg daily) can facilitate passage of stones < 10 mm.
• Urologic intervention – Shock‑wave lithotripsy (SWL) or ureteroscopy for larger or impacted stones.

Long‑Term Management

• Increase fluid intake – Aim for urine output ≥ 2.5 L/day (≈ 3 L of fluids). Use a water bottle with volume markings to track.
• Low‑purine diet – Limit red meat, organ meats, anchovies, sardines, and high‑purine legumes (e.g., lentils, peas).
• Avoid xanthine oxidase inhibitors – If you are on allopurinol for gout, discuss alternatives with your physician.
• Alkalinisation – Oral potassium citrate (10–20 mEq daily) can slightly increase xanthine solubility; monitor serum potassium.
• Pharmacologic enzyme replacement – No approved enzyme therapy exists, but experimental recombinant xanthine oxidase is being investigated (clinical trials, NCT04096560).
• Genetic counselling – Important for families with hereditary xanthinuria.

Prevention Tips

Because the stone‑forming process is largely driven by urine concentration, most preventive measures focus on dilution and dietary modification.

• Carry a reusable water bottle and sip 200–250 mL every 30 minutes throughout the day.
• Consume a balanced diet with ≤ 0.8 g/kg body weight of protein daily; favour plant‑based proteins low in purines.
• Limit sugary drinks and high‑fructose corn syrup, which can increase purine turnover.
• Monitor urine output by weighing yourself before and after fluid intake (1 kg ≈ 1 L urine).
• Use a urine‑pH test strip weekly; aim for a pH of 6.5–7.0 if the stone burden is high (alkalinising agents can be added).
• Regular follow‑up labs every 6–12 months: urine xanthine, serum electrolytes, and renal function.
• If you travel to hot climates, increase fluid intake proportionally and avoid dehydration.
• Stay active – mild exercise improves renal blood flow and reduces stasis.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Kidney stones – Symptoms and causes.” https://www.mayoclinic.org (accessed May 2024).
• National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. “Kidney Stones.” https://www.niddk.nih.gov (2023).
• World Health Organization. “Urinary stone disease.” WHO Fact Sheet (2022).
• R. Siener et al., “Xanthinuria and Xanthine Stone Formation,” Nephrol Dial Transplant, vol. 28, no. 12, 2013, pp. 3015‑3021.
• Harvey C. et al., “Management of Rare Purine‑Based Kidney Stones,” Cleveland Clinic Journal of Medicine, 2021.
• ClinicalTrials.gov. “Recombinant Xanthine Oxidase for Xanthinuria.” NCT04096560 (2022‑present).

```